---
title: "Eloxx Pharmaceuticals, Inc. (ELOX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ELOX.US.md"
symbol: "ELOX.US"
name: "Eloxx Pharmaceuticals, Inc."
industry: "Pharmaceuticals"
datetime: "2026-06-13T14:57:24.764Z"
locales:
  - [en](https://longbridge.com/en/quote/ELOX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ELOX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ELOX.US.md)
---

# Eloxx Pharmaceuticals, Inc. (ELOX.US)

## Company Overview

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.eloxxpharma.com](https://www.eloxxpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -6.79 | 176 | - | - | - |
| PB | -7.20 | 224 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ELOX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ELOX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ELOX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ELOX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**